Publication:
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023

Simple item page
dc.contributor.authorFontán-Vela, Mario
dc.contributor.authorKissling, Esther
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorBraeye, Toon
dc.contributor.authorVan Evercooren, Izaak
dc.contributor.authorHolm Hansen, Christian
dc.contributor.authorEmborg, Hanne-Dorthe
dc.contributor.authorFabiani, Massimo
dc.contributor.authorMateo-Urdiales, Alberto
dc.contributor.authorAlKerwi, Ala'a
dc.contributor.authorSchmitz, Susanne
dc.contributor.authorCastilla, Jesús
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorde Gier, Brechje
dc.contributor.authorHahné, Susan
dc.contributor.authorMeijerink, Hinta
dc.contributor.authorStarrfelt, Jostein
dc.contributor.authorNunes, Baltazar
dc.contributor.authorCaetano, Constantino
dc.contributor.authorDerrough, Tarik
dc.contributor.authorNardone, Anthony
dc.contributor.authorMonge Corella, Susana
dc.contributor.authorVEBIS-Lot4 working group
dc.date.accessioned2024-03-18T12:38:22Z
dc.date.available2024-03-18T12:38:22Z
dc.date.issued2024-01
dc.description.abstractTo monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds.es_ES
dc.description.peerreviewedSíes_ES
dc.format.number1es_ES
dc.format.page2300670es_ES
dc.format.volume29es_ES
dc.identifier.citationEuro Surveill. 2024 Jan;29(1):2300670.es_ES
dc.identifier.doi10.2807/1560-7917.ES.2024.29.1.2300670es_ES
dc.identifier.e-issn1560-7917es_ES
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.identifier.pubmedID38179626es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18983
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2024.29.1.2300670es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19es_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectCohort designes_ES
dc.subjectElectronic health recordses_ES
dc.subjectHospitalisationes_ES
dc.subjectMulti-country studyes_ES
dc.subjectVaccine effectivenesses_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshHumanses_ES
dc.titleRelative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023es_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationacb2d83b-fdee-49ed-8169-8b093c906160
relation.isAuthorOfPublication7ac13a7f-3d30-4846-8b51-b7505c7df45c
relation.isAuthorOfPublicationa0bb4f4f-11f0-487e-bf93-0b13f90057cc
relation.isAuthorOfPublication.latestForDiscoveryacb2d83b-fdee-49ed-8169-8b093c906160
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
RelativeVaccineEffectivenessAgainstCOVID-19_2024.pdf
Size:
358.23 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Centro Nacional de Epidemiología (CNE)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)